pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 20·1 min read
save

STAT invites reader debate on blue zones and open-access publishing fees

Jun 20, 2026·read at STAT ↗Neutral

Torie Bosch, editor of STAT’s First Opinion platform, has published an opinion piece encouraging readers to submit letters responding to recent essays.

The article explains that STAT will publish selected letters to foster good‑faith discussion, and provides a link for submissions at the end of each First Opinion essay.

Among the topics highlighted for debate are the reality of so‑called blue zones and the cost of open‑access publishing fees, with Bosch noting her two‑decade experience covering blue zones for National Geographic.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: STAT readers debate blue zones, open-access publishing fees, and more”

read at STAT ↗
3,452 words · retrieved Jun 20
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADINGUniversity of IowaWM TECHNOLOGY, INC.
topics
ImmunologyOncologyPlatform CompanyType 2 Diabetes

related stories

  • Dec 22Fierce Biotech Fundraising Tracker '26: Matchpoint makes $150M; KymaThera corrals $80MFierce Biotech
  • Sep 29Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand HengruiFierce Biotech
  • Sep 24Lilly’s latest China drug deal; Immunovant’s setback in lupusBioPharma Dive
  • Sep 11This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spreeBioPharma Dive
  • Aug 31A winner, a loser, and a mid-stage signal from a major cardiology research conferenceSTAT